Cardiovascular-Kidney-Metabolic (CKM) Syndrome
Cardiovascular-Kidney-Metabolic Syndrome is the American Heart Association’s staging construct for the linked progression of metabolic risk, chronic kidney disease, and cardiovascular disease.
Also known as: CKM syndrome, cardiovascular-kidney-metabolic health, CKM health
CKM Syndrome is not a new organ system or a consumer identity. It is a clinical map for problems medicine has too often separated: excess adiposity, insulin resistance, high blood pressure, abnormal lipids, albuminuria, chronic kidney disease, heart failure, stroke, atrial fibrillation, and atherosclerotic cardiovascular disease.
The useful idea is simple. Heart, kidney, and metabolic risk usually travel together. A staging frame lets clinicians and readers ask where the risk sits now, what might move it, and where coordinated care needs to sit.
What It Is
Cardiovascular-Kidney-Metabolic (CKM) Syndrome is a staged description of interlocked risk across the cardiovascular, kidney, and metabolic systems. The American Heart Association introduced the construct in a 2023 presidential advisory, then the AHA, ACC, ADA, and ASN published the first comprehensive CKM Syndrome clinical practice guideline on June 9, 2026.
The staging construct runs from stage 0 through stage 4:
| Stage | Working meaning | Typical signals |
|---|---|---|
| 0 | No identified CKM risk factors | Good CKM health; primary focus is preserving it |
| 1 | Early adiposity or glucose-regulation risk | Excess or dysfunctional adiposity, insulin resistance, prediabetes |
| 2 | Metabolic risk factors, chronic kidney disease, or both | Hypertension, high triglycerides, type 2 diabetes, metabolic syndrome, CKD |
| 3 | Subclinical cardiovascular disease, very high-risk CKD, or high predicted cardiovascular risk | Silent atherosclerosis, early heart-failure signals, high PREVENT-estimated risk |
| 4 | Established cardiovascular disease in a CKM context | Coronary heart disease, heart failure, stroke, atrial fibrillation, peripheral artery disease, sometimes kidney failure |
This is vocabulary, not a protocol. CKM Syndrome does not tell a specific reader which drug, diet, scan, or weight-loss intervention to pursue. It names the combined risk frame that a clinician uses before making those decisions.
The stages are not meant to be a permanent identity. AHA patient materials frame CKM progression as something that can move forward or backward when risk factors change. That is one reason the stage needs a driver, a decision, and a responsible clinician rather than a label by itself.
The construct belongs near Evidence Tiers and The Longevity Pyramid. It is stronger than a wellness slogan because it is tied to guideline medicine. It is weaker than a proven longevity intervention because the label itself has not been shown to extend healthy human lifespan.
Why It Matters
Longevity conversations often split cardiometabolic risk into separate dashboards. A reader tracks ApoB, glucose, body composition, blood pressure, sleep, coronary calcium, eGFR, urine albumin, and GLP-1 eligibility as if each number belonged to a different project. CKM Syndrome says those projects are connected.
That matters because the same person can move through several risk domains at once. Abdominal adiposity can travel with insulin resistance and high triglycerides. Diabetes and hypertension can injure kidneys. Chronic kidney disease can raise cardiovascular risk. Heart failure, atrial fibrillation, and atherosclerotic disease can appear downstream from the same risk ecology.
The term also helps prevent false reassurance. A normal LDL-C doesn’t erase kidney risk. A better glucose trace doesn’t answer the particle-burden question. A weight-loss response does not automatically settle blood pressure, albuminuria, or subclinical atherosclerosis. The point is not to make every metric more frightening. It is to stop treating linked risks as separate errands.
CKM Syndrome also gives clinical escalation a cleaner place. Lifestyle work remains foundational, but selected people may need lipid-lowering therapy, blood-pressure management, kidney-protective drugs, GLP-1-based therapy, SGLT2 inhibition, metabolic and bariatric surgery, or specialty coordination. Those are clinician decisions. The CKM frame helps explain why they may belong to one risk plan rather than separate specialty silos.
How It Is Measured
CKM staging is assembled from ordinary clinical information, not from one proprietary test. The basic map usually includes adiposity measures, blood pressure, glucose status, lipid markers, kidney markers, cardiovascular history, and risk prediction.
The screening set named in AHA patient and professional materials includes blood glucose, blood pressure, lipid panel, urine albumin-to-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR), body mass index or waist circumference, and risk estimation with the PREVENT calculator. In selected cases, clinicians may add ApoB Screening, Lp(a) Screening, Coronary Artery Calcium Scoring, echocardiography, cardiac biomarkers, or other tests that refine risk.
The recognition test is practical:
| Question | CKM reading |
|---|---|
| Is the issue early risk, established disease, or silent organ damage? | Assign the stage conservatively from available clinical data. |
| Which axis is driving risk? | Separate adiposity, glucose, blood pressure, lipids, kidney function, and cardiovascular evidence. |
| What changes the decision? | Name the measurement or threshold before adding tests. |
| Who owns follow-up? | Identify the clinician or coordination point before risk gets split across specialties. |
CKM staging should narrow decisions. If it mainly creates more testing, it has drifted toward Biomarker Treadmill.
How It Plays Out
A 42-year-old with elevated waist circumference, prediabetes, and normal kidney markers may be discussed as stage 1. The useful move is not panic. It is recognizing that adiposity and glucose regulation now belong in the cardiovascular and kidney risk conversation, not only weight management.
A 56-year-old with hypertension, high triglycerides, type 2 diabetes, and mildly reduced eGFR may be discussed as stage 2. A glucose-only plan would be too narrow. Blood pressure, lipids, kidney protection, weight trajectory, and cardiovascular risk estimation all belong in the same clinical review.
A 64-year-old with high predicted 10-year cardiovascular risk, albuminuria, and coronary calcium may sit closer to stage 3 even without symptoms. That does not mean a larger scan package is automatically warranted. It means silent disease and predicted risk now have to guide clinician-owned decisions.
A longevity clinic can use CKM language well or badly. Used well, it coordinates cardiology, nephrology, endocrinology, primary care, nutrition, and exercise physiology around a measured risk map. Used badly, it becomes a premium label attached to another diagnostic bundle. The difference is whether staging changes decisions.
Evidence
Evidence tier: Practitioner consensus. CKM Syndrome is a guideline and staging construct, not a trial-proven longevity intervention. The evidence is strong that cardiovascular, kidney, and metabolic conditions are biologically and clinically linked. The evidence is weaker that naming the syndrome, by itself, improves outcomes.
The 2023 AHA presidential advisory defined CKM health, proposed staging from stage 0 to stage 4, and called for prevention, risk prediction, and care models that stop separating metabolic, kidney, and cardiovascular disease. Its value was conceptual and clinical: a shared language for a multisystem problem.
The PREVENT scientific statement added a risk-estimation layer. The equations estimate 10-year and 30-year total cardiovascular disease risk, including atherosclerotic cardiovascular disease and heart failure, and incorporate kidney function. Additional models can use UACR, hemoglobin A1c, and social-risk information when available. That is why CKM is more than a renamed metabolic syndrome.
The population signal is large. In a nationally representative NHANES analysis of 10,762 U.S. adults from 2011 through March 2020, Aggarwal, Ostrominski, and Vaduganathan estimated that 10.6% were stage 0, 25.9% stage 1, 49.0% stage 2, 5.4% stage 3, and 9.2% stage 4. In plain terms, almost 90% met criteria for stage 1 or higher, and 14.6% were in advanced stages 3 or 4. Advanced stages were more common with older age, among men, and among Black adults in that analysis.
The 2026 AHA/ACC/ADA/ASN guideline turned the construct into formal clinical guidance. It replaced and expanded the 2013 adult obesity guideline, used a literature search from October 29, 2024, through April 14, 2025, and targeted clinicians managing the spectrum of CKM Syndrome. The guideline emphasizes earlier risk detection, PREVENT-based risk assessment, routine metabolic and kidney assessment, social drivers of health, lifestyle management, coordinated interdisciplinary care, and selected therapies for obesity, diabetes, CKD, and cardiovascular risk.
The caveat is important. Most treatment evidence remains component-specific. Blood-pressure control, lipid management, GLP-1-based therapy in selected groups, SGLT2 inhibitors in relevant indications, kidney-risk management, weight-loss interventions, and lifestyle programs each carry their own evidence base. CKM Syndrome organizes those claims. It does not upgrade all of them to the same tier.
Caveats and Open Questions
The first caveat is overbreadth. If nearly 90% of adults meet stage 1 or higher in one U.S. analysis, the label can become too broad to guide a reader unless the stage, driver, and decision are named. “I have CKM” is less useful than “my clinician is treating stage 2 CKM driven by hypertension, high triglycerides, and albuminuria.”
The second caveat is medicalization. Stage 1 can include adiposity or prediabetes signals before overt disease. That can help move care upstream. It can also make a reader feel labeled before a specific clinical plan exists. The frame is useful only when it clarifies risk and action.
The third caveat is silo replacement. CKM Syndrome can become a new silo if a clinic creates a CKM program without real coordination among primary care, cardiology, nephrology, endocrinology, nutrition, and exercise support.
The open question is implementation. A better framework does not automatically produce better care. The field still has to show that CKM staging improves detection, treatment selection, adherence, risk communication, and outcomes without creating unnecessary testing cascades.
Consequences
Benefits. CKM Syndrome gives the reader a more accurate map of ordinary longevity risk. It ties waist circumference, blood pressure, A1c, triglycerides, apoB, eGFR, UACR, coronary calcium, heart failure signals, and cardiovascular events into one clinical story. It also helps explain why boring risks often outrank exotic interventions.
The frame protects against Single-Biomarker Tunnel Vision. A person can’t reduce CKM risk to glucose, weight, LDL-C, kidney function, or a wearable score alone. Each marker has to answer its own question inside the larger map.
Liabilities. CKM Syndrome can become label inflation. A broad staging construct can make many adults feel newly diseased without telling them what to do next. It can also become Lifestyle Theater if the response is visible wellness behavior rather than measured risk reduction.
The practical use is restrained: CKM is a staging language for clinician-supervised risk interpretation. It can connect risks, rank decisions, and coordinate care. It should not become a diagnosis to self-manage, a reason to buy more testing, or a shortcut around the evidence tier of each intervention.
Related Articles
Sources
- Aggarwal, Rahul, John W. Ostrominski, and Muthiah Vaduganathan. “Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011-2020.” JAMA 331, no. 21 (2024): 1858-1860. https://doi.org/10.1001/jama.2024.6892
- American Heart Association. “2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome.” Professional Heart Daily. Updated June 9, 2026. https://professional.heart.org/en/science-news/2026-guideline-for-the-prevention-detection-evaluation-and-management-of-ckm-syndrome
- American Heart Association. “Understanding Staging for Cardiovascular-Kidney-Metabolic Syndrome (CKM Syndrome).” June 2026. https://professional.heart.org/en/science-news/-/media/3794C9A489854F4ABC9D23BF974B5657.ashx
- Khan, Sadiya S., Josef Coresh, Michael J. Pencina, Chiadi E. Ndumele, Janani Rangaswami, Sheryl L. Chow, Latha P. Palaniappan, et al. “Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association.” Circulation 148, no. 24 (2023): 1982-2004. https://doi.org/10.1161/CIR.0000000000001191
- Ndumele, Chiadi E., Janani Rangaswami, Sheryl L. Chow, Ian J. Neeland, Katherine R. Tuttle, Sadiya S. Khan, Josef Coresh, et al. “Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association.” Circulation 148, no. 20 (2023): 1606-1635. https://doi.org/10.1161/CIR.0000000000001184
- Ndumele, Chiadi E., Fatima Rodriguez, Dave L. Dixon, Sadiya S. Khan, Debabrata Mukherjee, Mandeep Bajaj, Sripal Bangalore, et al. “2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Journal of the American College of Cardiology. Published online June 9, 2026. https://doi.org/10.1016/j.jacc.2026.03.056
Medical and Legal Boundary
This entry is a reference, not medical advice. It describes published evidence, regulatory status, and common clinical practice patterns. It does not diagnose, prescribe, or replace a clinician’s judgment for a specific person.
CKM staging and treatment decisions should be made with qualified clinicians who can interpret age, sex, pregnancy status, symptoms, medical history, medications, family history, blood pressure, lipid markers, glucose markers, kidney function, urine albumin, cardiovascular testing, and social drivers of health. This entry does not recommend self-diagnosis, self-staging, medication changes, imaging, weight-loss drugs, surgery, or kidney-protective therapy.